Opfindelseskatalog – Københavns Universitet

Erhvervssamarbejde > Kommercialisering > Opfindelseskatalog

Opfindelseskatalog

Københavns Universitet ejer en række opfindelser som eksterne forskere og virksomheder kan købe licens til at anvende. Herunder findes et udvalg af de opfindelser, som aktuelt tilbydes. 

Du er velkommen til at kontakte Tech Trans Kontoret hvis du ønsker et overblik over aktuelle opfindelser inden for et specifikt fagområde (se kontaktoplysninger til højre).

Anti-counterfeiting system - Unbreakable physical encryption based on physical unclonable functions

Presented at the Danish IP Fair, May 2017

Counterfeit consumer goods, from designer bags to consumer electronics, introduce trillion dollar losses to industry and annually lead to the loss of thousands of jobs. This technology offers:

• Complete anti-counterfeiting protection (electronic components)
• Complete consumer protection towards falsified products (medicine/formula)
• Full brand protection (luxury goods)

Link: Read the full description

Patent application number: EP17152670.0

Contact:
Bo Stenhuus, Commercial Officer
Technology Transfer Office
E-mail: bo.stenhuus@adm.ku.dk
+45 2961 1382

Antibiotics against MRSA - Piperazine Inhibitors of Bacterial Gyrase and Topoisomerase IV

Presented at the Danish IP Fair, May 2017

A new class of synthetic antibiotics with excellent activity against Gram-positive bacteria and especially methicillin-resistant Staphylococcus aureus (MRSA) with slow resistance development compared to current drugs and promising hERG data. This new class of antibiotics possesses a simple chemical structure, which facilitates its rapid non costly preparation via chemical synthesis.

Link: Read the full description

Intellectual Property Rights: PCT patent application filed on March 2, 2016

Contact:
Peter Stein Nielsen, Commercial Officer
Technology Transfer Office
E-mail: Peter.nielsen@adm.ku.dk
+45 21 64 74 47

 

Antibody-drug conjugate (ADC) targeting the collagen receptor uPARAP

Presented at the Danish IP Fair, May 2017

Development of a novel drug for personalized therapy directed against sarcomas, glioblastoma and certain leukemias. These diseases are in urgent need for novel means of targeted treatment, and in many cases no curative option currently exists. In particular, among these diseases, this therapy is directed against primary bone cancer (osteosarcoma, a prominent cancer in young patients), and glioblastoma multiforme (the most malignant brain tumors). Additional, larger possible indications for treatment are e.g. breast cancer, prostate cancer and head- and neck cancer, where the target receptor has been demonstrated to be expressed by cells of the tumor stroma.

Link: Read the full description

Intellectual Property Rights: Priority founding patent application filed 5 February 2016 as PA 2016 70063. Novel data added October 2016 (PA 2016 70834) and in PCT application on February 03, 2017 (P4124PC00).

Contact:
Contact information
Niels Behrendt, Section head, D.Sc.
The Finsen Laboratory,
Rigshospitalet / BRIC, Univ. Cph., Denmark Tel.: (+45) 3545 6030
e-mail: niels.behrendt@finsenlab.dk

  

Developing a Scalable Cell Therapy for Type 1 Diabetes

Presented at the Danish IP Fair, May 2017

We have identified a unique cell surface marker that allows purification of the beta cell progenitor cells. This in combination with their simplified method for producing stem cell derived insulin cells from these purified progenitor cells results in a safer and more efficient final product.

Link: Read the full description

Intellectual Property Rights: PCT application filed on April 21, 2016.

Contact:
Peter Stein Nielsen, Commercial Officer
Technology Transfer Office
E-mail: Peter.nielsen@adm.ku.dk
+45 21 64 74 47

 

Colonoscopy Preparation - A Novel Bowel Cleansing Product

Presented at the Danish IP Fair, May 2017

Using the collective insight, knowledge and wisdom of the team, a formulation which retains the key, recommended, ingredients of the existing product but that rather than representing a burden is actually palatable. (it looks, smells, tastes and looks like caramel-pudding The changes are expected, if anything, to reduce the main side effects associated with the existing products such as nausea and bloatedness (we can do little as to the resulting “diarrhea”).

Link: Read the full description

Intellectual Property Rights:
A patents application has been filed. Danish Application number: PA 2016 70326, Submission number 1400009518, Priority: 18 May 2016

Contact:
Bo Stenhuus, Commercial Officer,
Technology Transfer Office
E-mail: bo.stenhuus@adm.ku.dk
+45 2961 1382  

 

EMBARC - Engineering modulators of brown adipose receptors

Presented at the Danish IP Fair, May 2017

We are developing compounds that stimulate the calorie-burning and blood sugar-lowering actions of a unique organ called brown adipose tissue.

Link: Read the full description

Intellectual Property Rights:
Intellectual property rights: Danish priority application filed in December, 2016

Contact:
Peter Stein Nielsen, Commercial Officer
Technology Transfer Office
E-mail: Peter.nielsen@adm.ku.dk
+45 21 64 74 47

 

Finding new anticancer drugs - Novel HT-screening methodology for simultaneous identification of different classes of molecules

Presented at the Danish IP Fair, May 2017

Screening methods for the identification of novel chemotherapeutic drugs are either too unspecific (for instance plain cell viability) or too specific, relying on the development of a specific assay for a specific target. Here we present a methodology that allows the simultaneous identification of molecules belonging to different types of therapeutic targets in one single assay. This method is based on the multi-parameter analysis of replication stress markers, aiming at discovering new classes of successful chemotherapeutic drugs and novel compounds that kill cancer cells by replication stress.

Link: Read the full description

Intellectual Property Rights: WO2016078670

Contact:
Bo Stenhuus, Commercial Officer
Technology Transfer Office
E-mail: bo.stenhuus@adm.ku.dk
+45 2961 1382

 

Gene editing tool - Protein based genome editing tool

Presented at the Danish IP Fair, May 2017

Precise gene editing tools are very important in developing cells with novel properties. However it is unclear who has the intellectual rights to the tool such as Cas9/CRISPR. UCPH now has a new proprietary tool very suitable for precise gene editing BurrH. BurrH has several advantages over other emerging genome editing tools higher specificity, can be more easily fused with other peptides and enzymatic activities (e.g. nucleases, transcription factors). It is smaller than other gene editing tools such as TALAE and so it can be easier to transfect into a host cell.

Link: Read the full description

Intellectual Property Rights:
The invention is protected in a non-published patent application

Contact:
Bo Stenhuus, Commercial Officer
Technology Transfer Office
e-mail: Bo.stenhuus@adm.ku.dk 
+45 2961 1382

 

IBdetect: RNA-based diagnosis of inflammatory bowel disease

IBDetectTM is ideal for a ready-to-use diagnostic kit. It will reduce waste of healthcare resources and improve the quality of life for IBD patients.
• It is cheap and easy to implement – qPCR equipment is already widely available at hospitals
• It is quick to use – analysis can be completed within the same time frame as histological examination
• It can significantly increase the quality of IBD treatment without burdening the patient

Link: Read the full description

Intellectual Property Rights:
A priority patent application was filed on 07 July 2017.

Contact:
Liv Søndergaard Thomsen, Commercial Officer
Technology Transfer Office
E-mail: liv.thomsen@adm.ku.dk
+45 2057 0297  

 

Lipid-Polymer Hybrid Nanoparticles for Oligonucleotide Delivery - An innovative and efficient platform technology for local and systemic delivery

Presented at the Danish IP Fair, May 2017

Thermostable and inhalable dry powder formulation of lipidoid-polymer hybrid nanoparticles (LPNs) for efficient local and/or systemic delivery of oligonucleotides, e.g. siRNA, and single stranded antisense oligonucleotides.

Link: Read the full description

Intellectual Property Rights:
A European patent application has been filed on March 17, 2016 and PCT update on March 16, 2017

Contact:
Peter Stein Nielsen, Commercial Officer
Technology Transfer Office
E-mail: Peter.nielsen@adm.ku.dk
+45 21 64 74 47


 

MABs Targeting ADAM12 in Cancer - A novel approach to anti-invasive and anti-metastatic treatment

Presented at the Danish IP Fair, May 2017

By using monoclonal antibodies targeting ADAM12 it is possible to prevent metalloprotease MT1-MMP (MMP14)-mediated degradation of the cellular matrix (ECM). Thus, ADAM12 represents a target for anti-invasive and anti-metastatic treatment, which remains an underexplored field in cancer treatment. ADAM12 is expected to be a good cancer drug target because it is expressed at very low levels in normal adult tissues. Yet, it is upregulated upon tissue injury or excessive growth as seen in cancer or re-generation.

Link: Read the full description

Intellectual Property Rights: PCT application: WO 2015028027

Contact:
Ole Wiborg, Consulting Commercial Officer
E-mail: ow@wiborg.com
+45 40 96 80 18

 

Novel principles for osteoporosis treatment

Presented at the Danish IP Fair, May 2017

• Dual receptor agonist
• Small peptide backbone
• High potency
• High specificity

Based on published and unpublished data of ligand binding-modes to the GIP and GLP-2 receptors, we were able to develop GIPR/GLP-2R co-agonists of which the best two had potencies of maximum 6-fold difference compared to the native hormones on these two receptors.

Link: Read the full description

Intellectual Property Rights: Danish priority patent application filed on October 12, 2016

Contact:
Peter Stein Nielsen, Commercial Officer
Technology Transfer Office
E-mail: Peter.nielsen@adm.ku.dk
+45 21 64 74 47


 

Pollution Control Using Oxygen - Inexpensive New Method for Cleaning Hot Exhaust air

The present invention relates to a method for cleaning a polluted airstream using the reactive species generated by pyrolysis of ozone. Adding ozone to an airstream passing over a reaction surface above 50 °C triggers formation of reactive species from the ozone, which subsequently counter the pollution. In contrast to current technologies, the reaction surface is not a catalyst. It is therefore possible to use materials already known in the ventilation and construction industries.

Link: Read the full description

Intellectual Property Rights: PCT/EP2017/064787

Contact:
Klavs Riishede Hansen, Commercial Officer
Technology Transfer Office/RegionH
E-mail: krh@adm.ku.dk
+45 93 56 57 40

 

Restriction Enzymes v2.0 – New set of restriction enzymes.

Presented at the Danish IP Fair, May 2017

Restriction enzymes (REs) are vastly used in many fields in science from traditional cloning experiments to DNA mapping. There are 2 major limitations in the canonical REs

1. each REs recognize one specific sequence, and while the number of these enzymes is quite large they are not yet enough to recognized all possible DNA sequences.

2. each canonical REs is a different proteins, and although many of them are produced recombinantly, each REs require some adjustments in the production to maximise the yield, this will ultimately affect the cost of the products. UCPH now has a new proprietary tool to generate RE version 2.0 that do not have these limitations.

This new class of REs is made of a constant protein part (Cpf1), and of a variable RNA part that will provide the DNA specificity to the enzyme. The assembled of these two components will produce enzymes able to cut any user-defined DNA sequences. Furthermore,  in this RE-2.0, because the RNAs are quite short (42 bases) their production is very easy and standard. This together with the fact that the protein, Cpf1 is the same in all enzymes, will allow the production of all the RE-2.0 with a single protocol and at the same cost.

Link: Read the full description

Intellectual Property Rights: The invention is protected in a non-published patent application

Contact:
Bo Stenhuus, Commercial Officer,
Technology Transfer Office
E-mail: bo.stenhuus@adm.ku.dk
+45 2961 1382

 

Targeting TONSL for cancer therapy - Structure-based design of novel small molecule inhibitors

Presented at the Danish IP Fair, May 2017

Under a pre-seed grant from the Novo Nordisk Foundation we are working with external partners in USA, Canada and France on designing and syntesizing novel small molecule inhibitors. In parallel, we are aiming at validating TONSL as a clinically relevant cancer target through a number of in-vitro and in-vivo screens of cells and animal models. The focus is to determine what type of cancers could benefit most from treatment with TONSL inhibitors.

Link: Read the full description

Intellectual Property Rights:
Intellectual property rights: PCT application submitted 2016

Contact:
Structure based drug design - Thomas Frimurer (KU)
Ole Wiborg, Consulting Commercial Officer
ow@wiborg.com
+45 40 96 80 18

 

Therapy for IBD - Rectal therapy with compound X – an investment opportunity

Presented at the Danish IP Fair, May 2017

We have invented a novel therapeutic principle for treatment of inflammatory bowel disease and the therapy is especially well suited for the treatment of ulcerative colitis. The current state-of-the-art therapy for IBD targets the immune system and involves the uses of 5-aminosalicylates, steroids, thiopurines and biological therapies such as e.g. anti-tumor necrosis factor alpha antibodies.

The unique properties of the therapy are:

• Based on the repurposing of a known substance – compound X
• Targeting the epithelium rather than the immune system
• Anti-tumorigenic effect in the

Link: Read the full description

Intellectual Property Rights: EP priority patent application filed on November 14, 2016

Contact:
Peter Stein Nielsen, Commercial Officer
Technology Transfer Office
E-mail: Peter.nielsen@adm.ku.dk
+45 21 64 74 47

 

Unique or Custom Probes - Exclusive or made-to-order fluorescent dyes KU-dyes.com

Presented at the Danish IP Fair, May 2017

Dyes are high value products. KU dyes operate on three tracks. The first is by exploiting the new unique probes exclusive to KU Dyes (IP protected). The second is to build value through documentation, supplying dyes for products in regulated markets. The third is establishing new product lines through individual R&D projects.

Link: Read the full description

Intellectual Property Rights:
20 /1/2016 - Substituted acridine-like and xanthenium-like fluorescent dyes PCT/DK2016/0

Contact:
KU Dyes ApS,
Universitetsparken 5,
2100 København Ø
E-mail: BWL@ku-dyes.com / TJS@ku-dyes.com 
+45 28 569 557
www.ku-dyes.com